The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Multiple Sclerosis, Myasthenia Gravis
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
University of California, Irvine, Irvine, California, United States, 92697
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218
Local Institution - 0032, New Haven, Connecticut, United States, 06510
University of Kansas Medical Center, Kansas City, Kansas, United States, 66160
Local Institution - 0039, New Orleans, Louisiana, United States, 70121
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
Hackensack University Medical Center, Hackensack, New Jersey, United States, 07601
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 60 Years
ALL
No
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-07-15